Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Gentherm, with a focus on how actual results compare to estimates, which could significantly influence the stock price [1][2]. Earnings Expectations - Gentherm is expected to report quarterly earnings of $0.57 per share, reflecting a year-over-year increase of +96.6% [3]. - Revenue is projected to be $374.72 million, representing a 6.2% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 4.46% over the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Gentherm matches the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from the consensus estimate, with a strong predictor for positive readings [9][10]. - Gentherm currently holds a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively [12]. Historical Performance - In the last reported quarter, Gentherm exceeded the expected earnings of $0.64 per share, achieving $0.73, which was a surprise of +14.06% [13]. - Over the past four quarters, Gentherm has beaten consensus EPS estimates twice [14]. Market Context - The automotive industry player Dana is expected to post earnings of $0.32 per share, indicating a year-over-year change of +28%, with revenues expected to decline by 20.4% to $1.86 billion [18][19]. - Dana's consensus EPS estimate has been revised up by 9.4% in the last 30 days, but it also has an Earnings ESP of 0.00% [19][20].

The market expects American Coastal Insurance (ACIC) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expect ...

Core Viewpoint - Akamai Technologies (AKAM) is expected to report a year-over-year increase in earnings and revenues for the quarter ended December 2025, with the actual results being crucial for its near-term stock price movement [1][2]. Earnings Expectations - The consensus estimate for Akamai's upcoming quarterly earnings is $1.75 per share, reflecting a year-over-year increase of +5.4% [3]. - Revenues are anticipated to reach $1.08 billion, which is a +5.6% increase from the same quarter last year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised 0.13% higher, indicating a positive reassessment by analysts [4]. - The Most Accurate Estimate for Akamai is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +1.02%, suggesting a bullish outlook from analysts [11]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [9]. - Akamai currently holds a Zacks Rank of 3, which, along with the positive Earnings ESP, suggests a likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Akamai exceeded the expected earnings of $1.64 per share by delivering $1.86, resulting in a surprise of +13.41% [12]. - The company has successfully beaten consensus EPS estimates in all of the last four quarters [13]. Industry Context - In comparison, DoorDash, Inc. (DASH) is expected to report earnings of $0.58 per share for the same quarter, indicating a year-over-year change of +75.8%, with revenues projected at $3.97 billion, up 38.2% from the previous year [17]. - However, DoorDash's consensus EPS estimate has been revised down by 3% over the last 30 days, resulting in an Earnings ESP of -1.72% and a Zacks Rank of 4 (Sell), making it difficult to predict an earnings beat [18].

Core Viewpoint - BridgeBio Pharma (BBIO) is expected to report a year-over-year increase in earnings driven by higher revenues, with the consensus outlook being crucial for assessing the company's earnings picture [1] Earnings Expectations - The consensus EPS estimate for BridgeBio Pharma is a loss of $0.74 per share, reflecting a year-over-year change of +43.5% [3] - Revenues are anticipated to reach $150.47 million, representing a significant increase of 2459% from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised 1.1% higher in the last 30 days, indicating a collective reassessment by analysts [4] - The Most Accurate Estimate for BridgeBio Pharma is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -2.69%, suggesting a bearish outlook from analysts [12] Earnings Surprise History - In the last reported quarter, BridgeBio Pharma was expected to post a loss of $0.88 per share but actually reported a loss of -$0.95, resulting in a surprise of -7.95% [13] - Over the past four quarters, the company has only beaten consensus EPS estimates once [14] Industry Comparison - Bausch Health (BHC), another player in the Zacks Medical - Generic Drugs industry, is expected to report earnings of $1.21 per share, with a year-over-year change of +5.2% and revenues of $2.7 billion, up 5.7% from the previous year [18][19] - Bausch's consensus EPS estimate has been revised 0.6% higher, but a lower Most Accurate Estimate has resulted in an Earnings ESP of -8.84%, making it difficult to predict an earnings beat [19][20]

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Celsius Holdings Inc. (CELH) due to higher revenues, with actual results being crucial for stock price movement [1] Earnings Expectations - The consensus EPS estimate for Celsius is $0.19 per share, reflecting a year-over-year increase of +35.7% [3] - Expected revenues are $638.18 million, which is a significant increase of 92.1% from the previous year [3] Estimate Revisions - The consensus EPS estimate has been revised 0.59% higher in the last 30 days, indicating a positive reassessment by analysts [4] - The Most Accurate Estimate for Celsius is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +6.46% [12] Earnings Surprise Prediction - A positive Earnings ESP is a strong indicator of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10] - Celsius currently holds a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate [12] Historical Performance - In the last reported quarter, Celsius exceeded the expected earnings of $0.28 per share by delivering $0.42, resulting in a surprise of +50.00% [13] - Over the past four quarters, Celsius has beaten consensus EPS estimates three times [14] Industry Context - In contrast, Medifast (MED), a competitor in the Zacks Food - Miscellaneous industry, is expected to report a loss of $0.76 per share, indicating a year-over-year change of -860% [18] - Medifast's expected revenue is $70.81 million, down 40.5% from the previous year [18]

Core Viewpoint - Esab (ESAB) is anticipated to report a year-over-year increase in earnings driven by higher revenues, with the actual results having a significant impact on its near-term stock price [1][2]. Earnings Expectations - The upcoming earnings report is expected to show quarterly earnings of $1.34 per share, reflecting a year-over-year increase of +4.7% [3]. - Revenues are projected to reach $687.72 million, which is an 8.6% increase compared to the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 2.29% over the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Esab is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +0.19% [12]. Earnings Surprise Prediction - A positive Earnings ESP is a strong indicator of a potential earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10]. - Esab currently holds a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Esab exceeded the expected earnings of $1.27 per share by delivering $1.32, resulting in a surprise of +3.94% [13]. - Over the past four quarters, Esab has consistently beaten consensus EPS estimates [14].

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Deere (DE) despite higher revenues, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - Deere is expected to report quarterly earnings of $1.92 per share, reflecting a year-over-year decrease of 39.8%, while revenues are projected at $7.6 billion, an increase of 11.7% from the previous year [3]. - The earnings report is scheduled for release on February 19, and better-than-expected results could lead to a stock price increase, whereas missing estimates may result in a decline [2]. Estimate Revisions - The consensus EPS estimate has been revised 0.07% higher in the last 30 days, indicating a slight bullish sentiment among analysts [4]. - The Most Accurate Estimate for Deere is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +0.13%, suggesting a likelihood of beating the consensus EPS estimate [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10]. - Historically, Deere has beaten consensus EPS estimates three out of the last four quarters, which may influence future earnings predictions [14]. Industry Comparison - CNH Industrial (CNH), a competitor in the agricultural equipment sector, is expected to report earnings of $0.11 per share, a year-over-year decline of 26.7%, with revenues projected at $5.02 billion, up 2.9% from the previous year [18]. - CNH's consensus EPS estimate has remained unchanged, but a higher Most Accurate Estimate has resulted in an Earnings ESP of +4.08%, combined with a Zacks Rank of 4, making predictions of an earnings beat challenging [19].

Company Overview - Arrow Electronics Inc. is one of the world's largest distributors of electronic components and enterprise computing products, providing a broad range of products and value-added services to enhance customer competitiveness [12]. Investment Rating - Arrow Electronics has a Zacks Rank of 1 (Strong Buy) and a VGM Score of A, indicating strong potential for investment [13]. Performance Metrics - The stock has shown significant momentum, with shares up 36% over the past four weeks [13]. - Three analysts have revised their earnings estimates higher for fiscal 2026, with the Zacks Consensus Estimate increasing by $1.22 to $13.08 per share [13]. - Arrow Electronics boasts an average earnings surprise of +17.9% [13]. Investment Strategy - With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, Arrow Electronics is recommended for investors looking for strong growth potential [14].

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market engagement and confidence [1][2] Zacks Style Scores - Zacks Style Scores are indicators that assist investors in selecting stocks likely to outperform the market within 30 days, rated from A to F based on value, growth, and momentum characteristics [3] - The Value Score focuses on identifying undervalued stocks using financial ratios like P/E and Price/Sales [4] - The Growth Score evaluates a company's financial health and future outlook, analyzing projected earnings and sales for sustainable growth [5] - The Momentum Score capitalizes on price trends, using factors like weekly price changes to identify high-momentum stocks [6] - The VGM Score combines all three Style Scores, providing a comprehensive rating based on value, growth, and momentum [7] Zacks Rank and Style Scores Interaction - The Zacks Rank, based on earnings estimate revisions, has shown a strong historical performance, with 1 (Strong Buy) stocks yielding an average annual return of +23.83% since 1988, significantly outperforming the S&P 500 [8] - There are over 800 stocks rated, making it essential to utilize Style Scores to narrow down choices [9] - For optimal returns, stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B are recommended [10] - Stocks rated 4 (Sell) or 5 (Strong Sell) should be avoided, even if they have high Style Scores, due to their declining earnings forecasts [11] Company Spotlight: Robinhood Markets, Inc. - Robinhood Markets, Inc. is a financial services company offering commission-free trading in various financial instruments, aiming to democratize finance [12] - Currently rated 3 (Hold) by Zacks, Robinhood has a VGM Score of B and a Growth Style Score of A, indicating strong growth potential with a forecasted year-over-year earnings growth of 21% [13] - The company has seen positive revisions in earnings estimates, with the Zacks Consensus Estimate increasing by $0.16 to $2.48 per share for fiscal 2026 [13] - With a solid Zacks Rank and favorable Style Scores, Robinhood is positioned as a potential investment opportunity [14]

Company Overview - Illumina Inc. is based in San Diego, CA, and provides sequencing and array-based solutions for genetic and genomic analysis across various markets, including research and clinical settings. Its customer base includes genomic research centers, academic institutions, government laboratories, hospitals, and companies in pharmaceuticals, biotechnology, commercial molecular diagnostics, and consumer genomics [11]. Investment Ratings - Illumina has a Zacks Rank of 3 (Hold) and a VGM Score of A, indicating a solid position in the market [12]. - The company is considered a potential top pick for growth investors, with a Growth Style Score of A, forecasting a year-over-year earnings growth of 6.2% for the current fiscal year [12]. Earnings Estimates - In the last 60 days, five analysts have revised their earnings estimates higher for fiscal 2026, with the Zacks Consensus Estimate increasing by $0.10 to $5.14 per share [12]. - Illumina has an average earnings surprise of +10.1%, suggesting a positive trend in earnings performance [12]. Conclusion - With a strong Zacks Rank and top-tier Growth and VGM Style Scores, Illumina is recommended for investors' consideration [13].